X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
GSK Pharma Fact Sheet, GSK Pharma Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK Pharma Fact Sheet   (GLXO)

Here is the latest financial fact sheet of GSK Pharma. For more details, see the GSK Pharma quarterly results and GSK Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

GSK PHARMA Price History

Price Rs 2,426.3
Mkt Cap Rs m 205,503
Vol '000 0.0
P/E X 63.7
P/CF X 56.6
EPS (TTM) Rs 38.1
% ch % -0.1
No. of shares m 84.70
% ch week % -1.0
% ch 1-mth % -1.4
% ch 12-mth % -9.0
52 week H/L Rs 2,770.0/2,309.1
(As on Feb 19, 2018 09:33:00 AM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

GSK PHARMA Financials

No. of Mths
Year Ending
12
Dec-12
12
Dec-13
15
Mar-15
12
Mar-16
12
Mar-17
5-Yr Chart
Click to enlarge
GSK PHARMA EQUITY SHARE DATA
High Rs2,3383,0023,5503,8503,838 
Low Rs1,9162,0052,3522,9662,637 
Sales per share (Unadj.) Rs312.9302.6396.5335.1354.2 
Earnings per share (Unadj.) Rs66.356.955.744.439.8 
Diluted earnings per shareRs66.356.955.744.439.8 
Cash flow per share (Unadj.) Rs68.459.258.747.442.9 
Dividends per share (Unadj.) Rs50.0050.0062.5050.0030.00 
Adj. dividends per shareRs50.0050.0062.5050.0030.00 
Dividend yield (eoy) %2.42.02.11.50.9 
Book value per share (Unadj.) Rs236.9234.9288.6257.8236.9 
Adj. book value per shareRs236.9234.9288.6257.8236.9 
Shares outstanding (eoy) m84.7084.7084.7084.7084.70 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x6.88.37.410.29.1 
Avg P/E ratio x32.144.053.076.781.4 
P/CF ratio (eoy) x31.142.350.372.075.5 
Price / Book Value ratio x9.010.710.213.213.7 
Dividend payout %75.487.9112.2112.675.4 
Avg Mkt Cap Rs m180,157212,038249,933288,643274,216 
No. of employees `0004.75.04.74.64.7 
Total wages/salary Rs m2,9553,6214,9304,4344,830 
Avg. sales/employee Rs Th5,632.25,090.87,211.76,154.76,387.0 
Avg. wages/employee Rs Th627.9719.31,058.6961.61,028.3 
Avg. net profit/employee Rs Th1,194.0956.91,012.7815.8717.1 
GSK PHARMA INCOME DATA
Net Sales Rs m26,50525,62733,58528,37930,000 
Other income Rs m1,7461,7701,9991,228728 
Total revenues Rs m28,25127,39735,58429,60730,728 
Gross profit Rs m8,2615,2826,2834,7834,190 
Depreciation Rs m178199254250263 
Interest Rs m30000 
Profit before tax Rs m9,8266,8538,0285,7614,655 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m-1,482262-51923457 
Tax Rs m2,7252,2982,7932,0231,744 
Profit after tax Rs m5,6194,8174,7163,7613,368 
Gross profit margin %31.220.618.716.914.0 
Effective tax rate %27.733.534.835.137.5 
Net profit margin %21.218.814.013.311.2 
GSK PHARMA BALANCE SHEET DATA
Current assets Rs m26,46726,23925,87021,73716,742 
Current liabilities Rs m8,3648,8895,0025,7927,202 
Net working cap to sales %68.367.762.156.231.8 
Current ratio x3.23.05.23.82.3 
Inventory Days Days3949416852 
Debtors Days Days1614111621 
Net fixed assets Rs m1,3321,6202,4444,7778,635 
Share capital Rs m847847847847847 
"Free" reserves Rs m19,20419,03323,59420,98519,222 
Net worth Rs m20,06819,89724,44121,83220,069 
Long term debt Rs m4136261610 
Total assets Rs m30,01731,29532,24430,54930,038 
Interest coverage x3,276.3NMNMNMNM 
Debt to equity ratio x00000 
Sales to assets ratio x0.90.81.00.91.0 
Return on assets %18.715.414.612.311.2 
Return on equity %28.024.219.317.216.8 
Return on capital %41.535.730.726.525.5 
Exports to sales %0.70.40.200 
Imports to sales %8.112.312.914.90 
Exports (fob) Rs m196956340 
Imports (cif) Rs m2,1523,1594,3344,2370 
Fx inflow Rs m715625699519528 
Fx outflow Rs m4,1415,3807,6808,3207,193 
Net fx Rs m-3,426-4,755-6,981-7,801-6,665 
GSK PHARMA CASH FLOW
From Operations Rs m 3,136 2,813 3,409 1,389 2,360 
From Investments Rs m -1,097 1,890 1,776 4,990 3,008 
From Financial Activity Rs m -4,406 -4,941 -4,970 -6,383 -5,108 
Net Cashflow Rs m -2,367 -239 215 -4 260 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 0.0%
Foreign collaborators 50.7%
Indian inst/Mut Fund 10.2%
FIIs 23.8%
ADR/GDR 0.0%
Free float 15.4%
Shareholders 102,036
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Dr. Annie Besant Road, Worli, Mumbai - 400 030
E-MAIL ajay.a.nadkarni@gsk.com WEB www.gsk-india.com
TELEPHONE (022) 2495 9415 FAX (022) 2498 1526
SECTOR PHARMACEUTICALS GROUP M N C
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR Price Waterhouse & Co.
CHM: D. S. Parekh COMP SEC: A. A. Nadkarni (GM & Admin) YEAR OF INC: 1924 BSE CODE: 500660 FV (Rs): 10 DIV YIELD (%): 1.2

More Pharmaceuticals Company Fact Sheets:   CADILA HEALTHCARE  ASTRAZENECA PHARMA  UNICHEM LAB  SANOFI INDIA  MERCK LTD  

Compare GSK PHARMA With:   CADILA HEALTHCARE  ASTRAZENECA PHARMA  UNICHEM LAB  SANOFI INDIA  MERCK LTD  

Compare GSK PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Strong US Markets; SBI, Tata Steel & Other Top Cues to Sway the Markets Today(Pre-Open)

After opening the day in green, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GSK PHARMA

GSK PHARMA - MYLAN COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS